SAN DIEGO, April 6, 2016 /PRNewswire/ -- Mesa Biotech Inc., a privately-held, molecular diagnostic company developing a testing platform designed specifically for point-of-care infectious disease diagnosis, today announced that William R. Brody, M.D., Ph.D. has been appointed Mesa Biotech's Chairman of the Board.
As former president of San Diego's Salk Institute for Biological Studies, Brody led Salk to triple its endowment and created 19 endowed professorships over his six-year tenure. He attracted a new generation of the world's best researchers, instilling technological discipline into biological pursuits, and raising Salk's profile through ground breaking life sciences discoveries. Prior to Salk, Brody served as the president of Johns Hopkins University for 12 years.
Hong Cai, Co-founder and CEO of Mesa Biotech said, "We are exceptionally pleased to appoint Bill Brody as the Chairman of the Board of Mesa Biotech. His wealth of experience building and leading growth-oriented medical device companies and heading two world-renowned prestigious research organizations, combined with his vast network of professional connections, will be invaluable as we prepare to commercialize our first product."
"I am honored to be a part of this rapidly growing company," said Brody. "Their corporate mission of expanding accessibility and affordability of healthcare is closely aligned with my personal beliefs and background. I look forward to working closely with the executive team to move the company forward."
A native of Stockton, Calif., Dr. Brody received his bachelor's and master's degrees in electrical engineering from the Massachusetts Institute of Technology, and his doctorate degree (also in electrical engineering) and medical degree (M.D.) from Stanford University. He has co-founded three medical device companies, and previously served as the CEO of Resonex, Inc. Brody is a member of the National Academy of Engineering and the Institute of Medicine.
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory-quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa Biotech has raised over $10 million to date for R&D and clinical trials. The company is preparing for Series A funding and expects to obtain FDA approval for its first product, the influenza/RSV assay and dock in 2017. For more information visit www.mesabiotech.com.
SOURCE Mesa Biotech Inc.